NTLA
USDIntellia Therapeutics Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$8.200
高値
$8.445
安値
$8.060
出来高
9.93M
企業ファンダメンタルズ
時価総額
864.9M
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
4.19M
取引所
NGM
通貨
USD
52週レンジ
関連ニュース
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics with a Buy and lowers the price target from $74 to $54.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $10 price target.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。